|
|
||||||||||
|
J Am Coll Cardiol, 2007; 49:2081-2089, doi:10.1016/j.jacc.2006.08.069
(Published online 11 May 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,2




* Cardiovascular Biology Research Centre, Division of Cardiac and Vascular Sciences, St. Georges, University of London, London, United Kingdom
Analytical Unit, Division of Cardiac and Vascular Sciences, St. Georges, University of London, London, United Kingdom
University Cardiology Department, Democritus University of Thrace, Alexandroupolis, Greece.
Manuscript received March 14, 2006; revised manuscript received August 14, 2006, accepted August 21, 2006.
* Reprint requests and correspondence: Dr. Juan Carlos Kaski, Cardiovascular Biology Research Centre, Division of Cardiac and Vascular Sciences, St. Georges, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom. (Email: jkaski{at}sgul.ac.uk).
Objectives: We hypothesized that cholesterol content is increased in the circulating erythrocytes of patients with acute coronary syndrome (ACS) and may be a marker of clinical instability. We therefore sought to investigate whether cholesterol content differs in erythrocyte membranes of patients presenting with ACS compared to patients with chronic stable angina (CSA).
Background: Plaque rupture in ACS depends at least partly on the volume of the necrotic lipid core. Histopathologic studies have suggested that cholesterol transported by erythrocytes and deposited into the necrotic core of atheromatous plaques contributes to lipid core growth.
Methods: Consecutive angina patients were prospectively assessed; 120 had CSA (83 men, age 64 ± 11 years) and 92 ACS (67 men, 66 ± 11 years). Total cholesterol content in erythrocyte membranes (CEM) was measured using an enzymatic assay, and protein content was assessed by the Bradford method.
Results: The CEM (median and interquartile range) was higher (p < 0.001) in ACS patients (184 µg/mg; range 130.4 to 260.4 µg/mg) compared with CSA patients (81.1 µg/mg; range 53.9 to 109.1 µg/mg) (analysis of covariance). Total plasma cholesterol concentrations did not correlate with CEM levels (r = 0.046, p = 0.628).
Conclusions: This study shows, for the first time, that CEM is significantly higher in patients with ACS compared with CSA patients. These findings suggest a potential role of CEM as a marker of atheromatous plaque growth and vulnerability. Large ad hoc studies are required to establish the clinical importance and pathogenic significance of CEM measurement.
| ||||||||||||||
Related Article
J. Am. Coll. Cardiol. 2007 49: 2090-2092.
This article has been cited by other articles:
![]() |
J. A. Ambrose In Search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention? J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1539 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann and A. Lerman Atherosclerosis in the Back Yard J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2102 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Arbustini Total Erythrocyte Membrane Cholesterol: An Innocent New Marker or an Active Player in Acute Coronary Syndromes? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2090 - 2092. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |